Targeting the CD27L-CD27 axis might be a therapeutic strategy given the observation that patients with CD27L or CD27 mutations and deletions are at a higher risk of developing Hodgkin lymphoma (155). The gene discussed is CD70; the disease is Hodgkins lymphoma.